KindlyMD (NASDAQ:NAKA – Get Free Report) had its price target raised by investment analysts at B. Riley Financial from $11.00 to $13.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price objective would suggest a potential upside of 31.18% from the company’s previous close.
NAKA has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. TD Cowen increased their price objective on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, KindlyMD has an average rating of “Hold” and an average price target of $20.00.
View Our Latest Analysis on KindlyMD
KindlyMD Stock Down 1.4%
KindlyMD (NASDAQ:NAKA – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. The firm had revenue of $35.87 million for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. On average, research analysts expect that KindlyMD will post -12.87 EPS for the current fiscal year.
Insider Buying and Selling at KindlyMD
In other news, CEO David F. Bailey purchased 32,134 shares of the stock in a transaction dated Wednesday, August 19th. The shares were purchased at an average cost of $5.59 per share, with a total value of $179,629.06. Following the acquisition, the chief executive officer directly owned 32,134 shares of the company’s stock, valued at $179,629.06. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders acquired 41,904 shares of company stock worth $235,231. 24.49% of the stock is owned by corporate insiders.
Institutional Trading of KindlyMD
A number of hedge funds have recently bought and sold shares of NAKA. J. Derek Lewis & Associates Inc. bought a new stake in shares of KindlyMD during the 4th quarter valued at about $167,000. Waddell & Associates LLC bought a new position in shares of KindlyMD in the 4th quarter worth approximately $201,000. Arrington Capital Management LLC bought a new position in shares of KindlyMD in the 4th quarter worth approximately $1,028,000. UBS Group AG purchased a new position in shares of KindlyMD in the fourth quarter worth approximately $2,958,000. Finally, Yorkville Advisors Global LP purchased a new position in shares of KindlyMD in the fourth quarter worth approximately $3,265,000.
KindlyMD Company Profile
KindlyMD, Inc is a healthcare company focused on providing integrated care for patients with complex medical needs, including chronic pain and substance use disorders. Its care model combines primary care, behavioral health services and medication-assisted treatment, with an emphasis on coordinated, patient-centered treatment.
The company has operated clinics in Utah and has also used telehealth and other technology-enabled services to expand access to care. KindlyMD’s services are designed to support patients through ongoing treatment and recovery rather than addressing individual medical issues in isolation.
KindlyMD became a publicly traded company through a business combination involving Nakamoto Holdings, with its common stock trading on the Nasdaq under the symbol NAKA.
Recommended Stories
- Five stocks we like better than KindlyMD
- Paramount Skydance Clears a Major Warner Bros. Discovery Hurdle—Here’s What Comes Next
- Can Apple Overtake NVIDIA as the World’s Most Valuable Company?
- Meta Platforms’ Petal Cable Puts Corning at the Center of AI’s Bandwidth Boom
- Tesla’s Delivery Warning Barely Moved the Stock—Here’s What Investors Care About
Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.
